Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?

References

• Darwin C, Murray J, William C, et al. On the origin of species by means of natural selection, or, the preservation of favoured races in the struggle for life. London: John Murray, Albemarle Street; 1859.
   Google Scholar
• Risitano AM, Kook H, Zeng W, et al. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood. 2002;100(1):178–183. doi: 10.1182/blood-2002-01-0236.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364(9431):355–364. doi: 10.1016/S0140-6736(04)16724-X.
   PubMed Web of Science ®Google Scholar
• Zeng W, Maciejewski JP, Chen G, et al. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest. 2001;108(5):765–773. doi: 10.1172/JCI200112687.
   PubMed Web of Science ®Google Scholar
• Pagliuca S, Gurnari C, Awada H, et al. The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood. 2021;138(26):2781–2798. doi: 10.1182/blood.2021012900.
   PubMed Web of Science ®Google Scholar
• Oguz FS, Yalman N, Diler AS, et al. HLA-DRB1*15 and pediatric aplastic anemia. Haematologica. 2002;87(7):772–774.
   PubMed Web of Science ®Google Scholar
• Yari F, Sobhani M, Vaziri MZ, et al. Association of aplastic anaemia and Fanconi’s disease with HLA-DRB1 alleles. Int J Immunogenet. 2008;35(6):453–456. doi: 10.1111/j.1744-313X.2008.00810.x.
   PubMed Web of Science ®Google Scholar
• Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84(12):4257–4261. doi: 10.1182/blood.V84.12.4257.bloodjournal84124257.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570–1574. doi: 10.1182/blood.V100.5.1570.h81702001570_1570_1574.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001;98(13):3513–3519. doi: 10.1182/blood.v98.13.3513.
   PubMed Web of Science ®Google Scholar
• Savage SA, Viard M, O’HUigin C, et al. Genome-wide association study identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia. Am J Hum Genet. 2020;106(2):264–271. doi: 10.1016/j.ajhg.2020.01.004.
   PubMed Web of Science ®Google Scholar
• Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003;102(13):4567–4575. doi: 10.1182/blood-2002-11-3409.
   PubMed Web of Science ®Google Scholar
• Hirano N, Butler MO, Guinan EC, et al. Presence of anti-kinectin and anti-PMS1 antibodies in japanese aplastic anaemia patients. Br J Haematol. 2005;128(2):221–223. doi: 10.1111/j.1365-2141.2004.05317.x.
   PubMed Web of Science ®Google Scholar
• Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104(8):2425–2431. doi: 10.1182/blood-2004-05-1839.
   PubMed Web of Science ®Google Scholar
• Jankovicova B, Skultety L, Dubrovcakova M, et al. Overlap of epitopes recognized by anti-carbonic anhydrase I IgG in patients with malignancy-related aplastic anemia-like syndrome and in patients with aplastic anemia. Immunol Lett. 2013;153(1-2):47–49. doi: 10.1016/j.imlet.2013.07.006.
   PubMed Web of Science ®Google Scholar
• Lakota J, Lanz A, Dubrovcakova M, et al. Antibodies against carbonic anhydrase in patients with aplastic anemia. Acta Haematol. 2012;128(3):190–194. doi: 10.1159/000338826.
   PubMed Web of Science ®Google Scholar
• Qi Z, Takamatsu H, Espinoza JL, et al. Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia. Ann Hematol. 2010;89(12):1255–1263. doi: 10.1007/s00277-010-1020-3.
   PubMed Web of Science ®Google Scholar
• Goto M, Kuribayashi K, Takahashi Y, et al. Identification of autoantibodies expressed in acquired aplastic anaemia. Br J Haematol. 2013;160(3):359–362. doi: 10.1111/bjh.12116.
   PubMed Web of Science ®Google Scholar
• Takamatsu H, Feng X, Chuhjo T, et al. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood. 2007;109(6):2514–2520. doi: 10.1182/blood-2006-07-036715.
   PubMed Web of Science ®Google Scholar
• Kelkka T, Tyster M, Lundgren S, et al. Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia. Leukemia. 2022;36(9):2317–2327. doi: 10.1038/s41375-022-01654-6.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185–1196. doi: 10.1182/blood-2011-12-274019.
   PubMed Web of Science ®Google Scholar
• Young ME, Potter V, Kulasekararaj AG, et al. Haematopoietic stem cell transplantation for acquired aplastic anaemia. Curr Opin Hematol. 2013;20(6):515–520. doi: 10.1097/MOH.0b013e328365af83.
   PubMed Web of Science ®Google Scholar
• Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S119–S25. doi: 10.1016/j.bbmt.2009.09.013.
   PubMed Web of Science ®Google Scholar
• Dubey S, Shukla P, Nityanand S. Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. Ann Hematol. 2005;84(9):572–577. doi: 10.1007/s00277-005-1022-8.
   PubMed Web of Science ®Google Scholar
• Sloand E, Kim S, Maciejewski JP, et al. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100(4):1185–1191. doi: 10.1182/blood-2002-01-0035.
   PubMed Web of Science ®Google Scholar
• Selleri C, Maciejewski JP, Sato T, et al. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 1996;87(10):4149–4157. doi: 10.1182/blood.V87.10.4149.bloodjournal87104149.
   PubMed Web of Science ®Google Scholar
• Alvarado LJ, Huntsman HD, Cheng H, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019;133(19):2043–2055. doi: 10.1182/blood-2018-11-884486.
   PubMed Web of Science ®Google Scholar
• Bestach Y, Sieza Y, Attie M, et al. Polymorphisms in TNF and IFNG are associated with clinical characteristics of aplastic anemia in Argentinean population. Leuk Lymphoma. 2015;56(6):1793–1798. doi: 10.3109/10428194.2014.966707.
   PubMed Web of Science ®Google Scholar
• El Mahgoub IR, Afify RA, Botros SK, et al. Immunoregulatory cytokines gene polymorphisms in Egyptian patients affected with acquired aplastic anemia. Ann Hematol. 2014;93(6):923–929. doi: 10.1007/s00277-013-1992-x.
   PubMed Web of Science ®Google Scholar
• Lee YG, Kim I, Kim JH, et al. Impact of cytokine gene polymorphisms on risk and treatment outcomes of aplastic anemia. Ann Hematol. 2011;90(5):515–521. doi: 10.1007/s00277-010-1102-2.
   PubMed Web of Science ®Google Scholar
• Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol. 2004;126(5):682–685. doi: 10.1111/j.1365-2141.2004.05102.x.
   PubMed Web of Science ®Google Scholar
• Kook H, Risitano AM, Zeng W, et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood. 2002;99(10):3668–3675. doi: 10.1182/blood.v99.10.3668.
   PubMed Web of Science ®Google Scholar
• Giudice V, Feng X, Lin Z, et al. Deep sequencing and flow cytometric characterization of expanded effector memory CD8(+)CD57(+) T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia. Haematologica. 2018;103(5):759–769. doi: 10.3324/haematol.2017.176701.
   PubMed Web of Science ®Google Scholar
• Patel BA, Giudice V, Young NS. Immunologic effects on the haematopoietic stem cell in marrow failure. Best Pract Res Clin Haematol. 2021;34(2):101276. doi: 10.1016/j.beha.2021.101276.
   PubMed Web of Science ®Google Scholar
• Giudice V, Risitano AM, Selleri C. Infectious agents and bone marrow failure: a causal or a casual connection? Front Med. 2021;8:757730. doi: 10.3389/fmed.2021.757730.
   PubMed Web of Science ®Google Scholar
• Olsson T. Epstein barr virus infection and immune defense related to HLA-DR15: consequences for multiple sclerosis. Eur J Immunol. 2021;51(1):56–59. doi: 10.1002/eji.202049030.
   PubMed Web of Science ®Google Scholar
• Angelini DF, Serafini B, Piras E, et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220. doi: 10.1371/journal.ppat.1003220.
   PubMed Web of Science ®Google Scholar
• Hsieh YC, Chang ST, Huang WT, et al. A comparative study of flow cytometric T cell receptor Vβ repertoire and T cell receptor gene rearrangement in the diagnosis of large granular lymphocytic lymphoproliferation. Int J Lab Hematol. 2013;35(5):501–509. doi: 10.1111/ijlh.12041.
   PubMed Web of Science ®Google Scholar
• Zawit M, Bahaj W, Gurnari C, et al. Large granular lymphocytic leukemia: from immunopathogenesis to treatment of refractory disease. Cancers. 2021;13(17):4418. doi: 10.3390/cancers13174418.
   PubMed Web of Science ®Google Scholar
• Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007;35(1):13–20. doi: 10.1016/j.exphem.2006.09.002.
   PubMed Web of Science ®Google Scholar
• Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582–587. doi: 10.1126/science.aao4572.
   PubMed Web of Science ®Google Scholar
• Hazane Leroyer E, Ziegler C, Moulin C, et al. Filling the gap: the immune therapeutic armamentarium for relapsed/refractory Hodgkin lymphoma. JCM. 2022;11(21):6574. doi: 10.3390/jcm11216574.
   Google Scholar
• Gurnari C, Pagliuca S. Digging into the HLA pockets: a new association with acute leukaemias. Br J Haematol. 2023;200(2):123–125. doi: 10.1111/bjh.18529.
   PubMed Web of Science ®Google Scholar
• Boukouaci W, Rivera-Franco MM, Volt F, et al. Comparative analysis of the variability of the human leukocyte antigen peptide-binding pockets in patients with acute leukaemia. Br J Haematol. 2023;200(2):197–209. doi: 10.1111/bjh.18517.
   PubMed Web of Science ®Google Scholar
• Pagliuca S, Gurnari C, Hercus C, et al. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation. Res Sq. 2023. PMID: 37066269
   PubMedGoogle Scholar
• Ishigaki K, Lagattuta KA, Luo Y, et al. HLA autoimmune risk alleles restrict the hypervariable region of T cell receptors. Nat Genet. 2022;54(4):393–402. doi: 10.1038/s41588-022-01032-z.
   PubMed Web of Science ®Google Scholar
• Moutsianas L, Jostins L, Beecham AH, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 2015;47(10):1107–1113.
   PubMed Web of Science ®Google Scholar
• Krause-Kyora B, Nutsua M, Boehme L, et al. Ancient DNA study reveals HLA susceptibility locus for leprosy in medieval europeans. Nat Commun. 2018;9(1):1569. doi: 10.1038/s41467-018-03857-x.
   PubMedGoogle Scholar
• Menegatti J, Schub D, Schäfer M, et al. HLA-DRB1*15:01 is a co-receptor for Epstein-Barr virus, linking genetic and environmental risk factors for multiple sclerosis. Eur J Immunol. 2021;51(9):2348–2350. doi: 10.1002/eji.202149179.
   PubMed Web of Science ®Google Scholar
• Brown KE, Tisdale J, Barrett AJ, et al. Hepatitis-associated aplastic anemia. N Engl J Med. 1997;336(15):1059–1064. doi: 10.1056/NEJM199704103361504.
   PubMed Web of Science ®Google Scholar
• Kagan WA, Ascensão JA, Pahwa RN, et al. Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci U S A. 1976;73(8):2890–2894. doi: 10.1073/pnas.73.8.2890.
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Bacigalupo A, Bruno B, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of the EBMT aplastic anaemia working party. Br J Haematol. 2010;149(6):890–895. doi: 10.1111/j.1365-2141.2010.08194.x.
   PubMed Web of Science ®Google Scholar
• Pol S, Driss F, Devergie A, et al. Is hepatitis C virus involved in hepatitis-associated aplastic anemia? Ann Intern Med. 1990;113(6):435–437. doi: 10.7326/0003-4819-113-6-435.
   PubMed Web of Science ®Google Scholar
• Crespo J, de las Heras B, Rivero M, et al. Hepatitis G virus infection as a possible causative agent of community-acquired hepatitis and associated aplastic anaemia. Postgrad Med J. 1999;75(881):159–160. doi: 10.1136/pgmj.75.881.159.
   PubMed Web of Science ®Google Scholar
• Dame C, Hasan C, Bode U, et al. Acute liver disease and aplastic anemia associated with the persistence of b19 DNA in liver and bone marrow. Pediatr Pathol Mol Med. 2002;21(1):25–29. doi: 10.1080/pdp.21.1.25.29.
   PubMedGoogle Scholar
• Schenke C, Alejandre-Alcázar MA, Holter W, et al. Aplastic anemia following hepatitis associated with human herpesvirus 6. J Pediatr Gastroenterol Nutr. 2010;51(4):527–529. doi: 10.1097/MPG.0b013e3181e9636e.
   PubMed Web of Science ®Google Scholar
• Baranski B, Armstrong G, Truman JT, et al. Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1988;109(9):695–704. doi: 10.7326/0003-4819-109-9-695.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Papaioannou M, Sica M, et al. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(14):2753–2761. doi: 10.1182/blood-2012-11-469353.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Zaimoku Y, Scappini B, et al. Glycosylphosphatidylinositol-specific T cells, IFN-γ-producing T cells, and pathogenesis of idiopathic aplastic anemia. Blood. 2017;129(3):388–392. doi: 10.1182/blood-2016-09-740845.
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Bessler M, Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell. 1997;88(1):1–4. doi: 10.1016/s0092-8674(00)81850-4.
   PubMed Web of Science ®Google Scholar
• Young NS, Maciejewski JP, Sloand E, et al. The relationship of aplastic anemia and PNH. Int J Hematol. 2002;76(Suppl 2):168–172. doi: 10.1007/BF03165111.
   PubMed Web of Science ®Google Scholar
• Van Kamp H, Van Imhoff GW, Wolf MD, et al. The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;89(1):79–82. doi: 10.1111/j.1365-2141.1995.tb08907.x.
   PubMed Web of Science ®Google Scholar
• Hill A, de Latour RP, Kulasekararaj AG, et al. Concomitant immunosuppressive therapy and eculizumab use in patients with paroxysmal nocturnal hemoglobinuria: an international PNH registry analysis. Acta Haematol. 2023;146(1):1–13. doi: 10.1159/000526979.
   PubMedGoogle Scholar
• Pagliuca S, Risitano AM, De Fontbrune FS, et al. Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. Bone Marrow Transplant. 2018;53(1):105–107. doi: 10.1038/bmt.2017.220.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Pagliuca S, Patel BJ, et al. Implication of PIGA genotype on erythrocytes phenotype in paroxysmal nocturnal hemoglobinuria. Leukemia. 2021;35(8):2431–2434. doi: 10.1038/s41375-020-01113-0.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Takeda J, Hirose S, et al. Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1993;77(2):517–521. doi: 10.1084/jem.177.2.517.
   Google Scholar
• Araten DJ, Luzzatto L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006;108(2):734–736. doi: 10.1182/blood-2006-01-0256.
   PubMed Web of Science ®Google Scholar
• Clemente MJ, Przychodzen B, Hirsch CM, et al. Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. Leukemia. 2018;32(11):2507–2511. doi: 10.1038/s41375-018-0138-5.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Graham AC, Efanov A, et al. Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. Blood Cells Mol Dis. 2021;87:102528. doi: 10.1016/j.bcmd.2020.102528.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi: 10.3389/fimmu.2019.01157.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi: 10.1056/NEJMoa061648.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549. doi: 10.1182/blood-2018-09-876805.
   PubMed Web of Science ®Google Scholar
• Giudice V, Selleri C. Aplastic anemia: pathophysiology. Semin Hematol. 2022;59(1):13–20. doi: 10.1053/j.seminhematol.2021.12.002.
   PubMed Web of Science ®Google Scholar
• Cooper JN, Young NS. Clonality in context: hematopoietic clones in their marrow environment. Blood. 2017;130(22):2363–2372. doi: 10.1182/blood-2017-07-794362.
   PubMed Web of Science ®Google Scholar
• Zhu C, Lian Y, Wang C, et al. Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia. Blood. 2021;138(1):23–33. doi: 10.1182/blood.2020008966.
   PubMed Web of Science ®Google Scholar
• Pagliuca S, Gurnari C, Hercus C, et al. Molecular landscape of immune pressure and escape in aplastic anemia. Leukemia. 2023;37(1):202–211. doi: 10.1038/s41375-022-01723-w.
   PubMed Web of Science ®Google Scholar
• Przychodzen B, Makishima H, Sekeres MA, et al. Fanconi anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. Oncotarget. 2018;9(2):2050–2057. doi: 10.18632/oncotarget.23328.
   PubMedGoogle Scholar
• Pagliuca S, Gurnari C, Rubio MT, et al. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol. 2022;13:944872. doi: 10.3389/fimmu.2022.944872.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–167. doi: 10.1038/s41571-018-0142-8.
   PubMed Web of Science ®Google Scholar
• Young NS, Maciejewski JP. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes “why? Why? Why? J Clin Invest. 2000;106(5):637–641. doi: 10.1172/JCI11002.
   PubMed Web of Science ®Google Scholar
• Afable MG, II, Wlodarski M, Makishima H, et al. SNP array–based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011;117(25):6876–6884. doi: 10.1182/blood-2010-11-314393.
   PubMed Web of Science ®Google Scholar
• Mizumaki H, Hosomichi K, Hosokawa K, et al. A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia. Haematologica. 2021;106(6):1581–1590.
   PubMed Web of Science ®Google Scholar
• Zaimoku Y, Patel BA, Adams SD, et al. HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia. Blood. 2021;138(26):2799–2809. doi: 10.1182/blood.2021012895.
   PubMed Web of Science ®Google Scholar
• Zaimoku Y, Takamatsu H, Hosomichi K, et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood. 2017;129(21):2908–2916. doi: 10.1182/blood-2016-11-752378.
   PubMed Web of Science ®Google Scholar
• Babushok DV, Duke JL, Xie HM, et al. Somatic HLA mutations expose the role of class I-mediated autoimmunity in aplastic anemia and its clonal complications. Blood Adv. 2017;1(22):1900–1910. doi: 10.1182/bloodadvances.2017010918.
   PubMed Web of Science ®Google Scholar
• Olson TS, Frost BF, Duke JL, et al. Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities. JCI Insight. 2022;7(22):e163040. doi: 10.1172/jci.insight.163040.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Pagliuca S, Prata PH, et al. Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria. J Clin Oncol. 2023;41(1):132–142. doi: 10.1200/JCO.22.00710.
   PubMed Web of Science ®Google Scholar
• Groarke EM, Patel BA, Shalhoub R, et al. Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia. Leukemia. 2022;36(9):2328–2337. doi: 10.1038/s41375-022-01636-8.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Pagliuca S, Kewan T, et al. Is nature truly healing itself? Spontaneous remissions in paroxysmal nocturnal hemoglobinuria. Blood Cancer J. 2021;11(11):187. doi: 10.1038/s41408-021-00582-5.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Visconte V. From bone marrow failure syndromes to VEXAS: disentangling clonal hematopoiesis, immune system, and molecular drivers. Leuk Res. 2023;127:107038. doi: 10.1016/j.leukres.2023.107038.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Fabiani E, Falconi G, et al. From clonal hematopoiesis to therapy-related myeloid neoplasms: the silent way of cancer progression. Biology. 2021;10(2):128. doi: 10.3390/biology10020128.
   PubMedGoogle Scholar
• Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35–47. doi: 10.1056/NEJMoa1414799.
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347–2358. doi: 10.1182/blood-2016-12-754796.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124(17):2698–2704. doi: 10.1182/blood-2014-05-574889.
   PubMed Web of Science ®Google Scholar
• Lane AA, Odejide O, Kopp N, et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013;27(4):968–971. doi: 10.1038/leu.2013.30.
   PubMed Web of Science ®Google Scholar
• Babushok DV, Perdigones N, Perin JC, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015;208(4):115–128. doi: 10.1016/j.cancergen.2015.01.007.
   PubMed Web of Science ®Google Scholar
• Heuser M, Schlarmann C, Dobbernack V, et al. Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica. 2014;99(9):e165-7–e167. doi: 10.3324/haematol.2013.101642.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99(9):3129–3135. doi: 10.1182/blood.v99.9.3129.
   PubMed Web of Science ®Google Scholar
• Saumell S, Florensa L, Luño E, et al. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. Br J Haematol. 2012;159(3):311–321. doi: 10.1111/bjh.12035.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Prata PH, Catto LFB, et al. IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2023. doi: 10.1182/blood.2023020108.
   Google Scholar
• Reilly CR, Shimamura A. Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances. Blood. 2023;141(13):1513–1523. doi: 10.1182/blood.2022017739.
   PubMed Web of Science ®Google Scholar
• Kennedy AL, Myers KC, Bowman J, et al. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021;12(1):1334. doi: 10.1038/s41467-021-21588-4.
   PubMed Web of Science ®Google Scholar
• Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood. 2016;128(3):337–347. doi: 10.1182/blood-2016-01-636381.
   PubMed Web of Science ®Google Scholar
• Sun L, Babushok DV. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2020;136(1):36–49. doi: 10.1182/blood.2019000940.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Maciejewski JP. Aplastic anemia: quo vadis? Semin Hematol. 2022;59(1):54–55. doi: 10.1053/j.seminhematol.2021.12.001.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11–23. doi: 10.1056/NEJMoa2109965.
   PubMed Web of Science ®Google Scholar
• Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550. doi: 10.1056/NEJMoa1613878.
   PubMed Web of Science ®Google Scholar
• Drexler B, Passweg J. Current evidence and the emerging role of eltrombopag in severe aplastic anemia. Ther Adv Hematol. 2021;12:2040620721998126. doi: 10.1177/2040620721998126.
   Web of Science ®Google Scholar
• Patel BA, Groarke EM, Lotter J, et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood. 2022;139(1):34–43. doi: 10.1182/blood.2021012130.
   PubMed Web of Science ®Google Scholar
• Negoro E, Nagata Y, Clemente MJ, et al. Origins of myelodysplastic syndromes after aplastic anemia. Blood. 2017;130(17):1953–1957. doi: 10.1182/blood-2017-02-767731.
   PubMed Web of Science ®Google Scholar
• Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European bone marrow transplantation-severe aplastic anaemia working party. N Engl J Med. 1993;329(16):1152–1157. doi: 10.1056/NEJM199310143291603.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. doi: 10.1182/blood.2022015850.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi: 10.1038/s41375-022-01613-1.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140(12):1345–1377. doi: 10.1182/blood.2022016867.
   PubMed Web of Science ®Google Scholar
• Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008.
   Google Scholar
• Kewan T, Bahaj W, Durmaz A, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141(14):1768–1772. doi: 10.1182/blood.2022018896.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Gagelmann N, Badbaran A, et al. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023;37(3):717–719. doi: 10.1038/s41375-023-01820-4.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Prata PH, Bazzo Catto LF, et al. Molecular international prognostic scoring system (IPSS-M) in myelodysplastic syndromes arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2022;140(Supplement 1):5788–5789. doi: 10.1182/blood-2022-160458.
   Google Scholar